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ulti-drug-resistant tuberculosis (MDR-TB) is a threat to global health. In 2018, TB related death was 
estimated to be more than 1.5 million cases worldwide. Conventional diagnostic method, which requires 
a long time to get a result, causes delays in new cases discoveries that lead to delayed therapy. Further, 
delayed and inadequate therapy causes an increase in the level of resistance to anti-TB drugs that may lead to 
death. Therefore, diagnostic tools, which can detect quickly and accurately, are highly needed. Early and timely 
detection is crucial for globally effective TB control, but this is not popular in developing countries, especially in 
Asia. Therefore, the objective of this review is to provide current information on the use of NGS as a rapid 












































Advancements in Life Sciences – International Quarterly Journal of Biological Sciences 
A R T I C L E  I N F O  
 
 
Date Received:  
31/07/2020;  
Date Revised:  
21/08/2020;  





 1. Doctoral 
Program in Biomedical 
Science, Faculty of 
Medicine, Universitas 
Indonesia - Indonesia 
2. Department of 
Histology, Faculty of 
Medicine, Universitas 
Indonesia - Indonesia 
3. Stem Cell Medical 
Technology Integrated 





Indonesia, - Indonesia 






(IMERI), Faculty of 
Medicine Universitas 









How to Cite: 
Messah ADV, Pawitan JA. 
Next Generation Sequencing 
as Rapid Diagnosis of 
Multidrug Resistance 





Next Generation sequencing; 
Multi-Drug Resistance; 
Tuberculosis; Mycobacterium 





                        Advancements in Life Sciences  |  www.als-journal.com  |  November 2020  | Volume 8  |  Issue 1                               31         
 
als 
Next Generation Sequencing as Rapid Diagnosis of Multidrug Resistance Tuberculosis You’re reading 
Introduction  
In 2018, tuberculosis (TB) new cases and TB related 
death were estimated to be 10 million and 1.5 million 
cases respectively. There was a 2% annual decline in 
global TB incidence between 2017 and 2018, but this 
decline is far from enough to achieve the world’s pledge 
to end TB epidemic by 2030 [1]. Though global TB 
incidence and mortality rates have declined recently, 
efforts to control TB were hampered by increased multi-
drug resistant TB (MDR-TB), which were resistant to at 
least two first-line drugs (isoniazid, rifampicin, and 
ethambutol), especially in Asian countries [2, 3]. 
World Health Organization (WHO) reported that there 
were thirty countries with high TB burden, and among 
those countries twelve were located in Asia, i.e. Vietnam, 
Thailand, Philippines, Papua New Guinea, Pakistan, 
Myanmar, Indonesia, India, Korea, China, Cambodia 
and Bangladesh. Collectively, the Philippines (6%), 
Indonesia (8%), China (9%), and India (27%) contributed 
to half of all TB cases, and approximately 44%  was 
contributed by the Southeast Asia region [2, 4].  
Tuberculosis cases are increasing every year due to 
to the resistance developed by Mycobacterium 
tuberculosis against anti-tuberculosis drugs, especially 
in Asia. Conventional diagnostic method, which needs 
culturing of the bacteria, requires a long time to get a 
result, and causes delays in new cases discoveries that 
lead to delayed therapy. Further, delayed and 
inadequate therapy causes an increase in the level of 
resistance to anti-TB drugs that may lead to death.  
Therefore, diagnostic tools, which can detect quickly and 
accurately, are highly needed. 
Successful diagnosis and treatment of MDR-TB 
depends on drug susceptibility testing (DST). 
Conventionally, the diagnosis of drug resistance to 
Mycobacterium tuberculosis (MTB) is highly dependent 
on culture and DST in liquid or solid media. Those 
phenotypic results can be obtained after weeks to 
months of incubation. In addition, phenotypic testing are 
often inaccurate, especially for drugs such as 
pyrazinamide [5]. 
Identification and characterization using molecular test 
on genetic basis to  detect pathogenic mutations in MDR-
TB DNA samples have been used for diagnosis, 
determining prognosis, and prospective therapy. The 
latest development of next generation sequencing (NGS) 
has revolutionized the molecular test for MDR-TB 
diagnosis, especially in developed countries. NGS 
presents options for detecting the characteristics of 
mutation in MDR-TB [6, 7] that is not readily available in 
most Asian countries. 
Therefore, this review aimed to provide current 
information on the use of NGS as a rapid diagnostic tool 
of MDR-TB especially in Asian population, and to 
highlight the various MDR genes. For this purpose, we 
discussed MDR-TB, molecular mechanism of drug 
resistance in TB, MDR-TB diagnostic problems and 
solutions, NGS for whole-genome sequencing to 
diagnose MDR-TB, various NGS platforms, NGS 
methods, and application of NGS to detect variants of 
drug-resistant MTB especially in the Asian population. 
Methods 
Literature search strategy and selection criteria 
Literature search was done in PubMed/Medline and 
Google Scholar on 20th of May 2020, and the keywords 
used were combination of: “multidrug resistance”, 
“tuberculosis”, “diagnosis”, “Asian population” and “next 
generation sequencing”. All articles that provided 
information on MDR-TB, molecular mechanism of drug 
resistance in tuberculosis, MDR-TB diagnostic problems 
and solutions, various means to diagnose MDR-TB 
including NGS, various NGS platforms, NGS methods, 
and application of NGS to detect variants of drug-
resistant MTB were included. Where possible, articles 
were restricted to recent articles that were published in 
last 10 years, except the content was very important. In 
addition, existing suitable article in authors’ files were 
added.  Finally, 47 articles were selected to write this 
review. 
Discussion 
Multidrug resistant TB  
Primary TB is a disease due to MTB in a patient who has 
never taken anti-TB medication or has taken for less than 
a month [8]. Endogenous reactivation occurs when there 
is a reactivation of a previous infection that was 
contained by the host immune response [9]. Drug-
resistant TB is resistant to a usually used anti-TB. The 
way of drug-resistant TB transmission is the same as 
drug-susceptible TB [10].  MTB causes TB infection and 
is contagious in the form of MTB containing airborne 
particles, which are called droplet nuclei, of 1– 5 microns 
in diameter. MTB containing droplet nuclei are generated 
when a person with pulmonary or laryngeal 
TB sneezes, coughs, sings or shouts. TB transmission 
occurs when MTB containing droplet nuclei are inhaled 
by a person through the mouth or nose, and finally reach 
the alveoli of the lungs [11]. 
Drug-resistant TB can develop in two different ways 
that results in primary and secondary resistance. Primary 
resistance occurs due to initial infection with resistant 
organisms. Secondary resistance, or acquired 
resistance occurs during TB therapy, either due to an 
inadequate regimen, or the prescribed regimen is not 
taken appropriately. Conditions in which a person has an 
increased risk to contract drug-resistant TB are: 
exposure to a drug-resistant TB patient, or a TB patient 
who has got prior TB treatment but the treatment failed 
or relapse, and whose susceptibility test results are not 
known, or to a TB patient from an area with a high 
prevalence of drug resistance, or travel to one of these 
areas, or exposure to a person with continuous positive 
smear and cultures after two months of combination TB 
therapy [10, 12]. 
Molecular mechanism of drug resistance in 
tuberculosis 
There are two mechanisms of drug resistance in TB, 
intrinsic and acquired drug resistance. Intrinsic drug 
resistance of  MTB  is attributed to the structure of MTB 
wall, or the ability of MTB to produce a certain enzyme. 
Intrinsic resistant MTB has mycolic acid containing cell 
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wall, which causes low permeability to anti-tuberculosis 
drugs that is an important factor for natural antibiotic 
resistance. In addition, MTB can produce a β-lactamase, 
which is an enzyme that damages antibiotics with beta-
lactam structure, where the β-lactamase is coded by 
blaS and blaC [12-14]. The acquired drug resistance is 
due to an inappropriate drug regimen or suboptimal TB 
treatment, which triggers spontaneous genetic mutations 
in chromosome genes, and causes resistance. The rate 
of mutation for most anti-TB drugs for one TB drug per 
cell division is around 10-9 and will be 10-18 for two kinds 
of TB drugs; thus this fact is the main reason why anti-
TB drugs are given in combination [15]. 
Mutations that cause isoniazid resistance may occur in 
various genes, namely katG, ahpC, inhA, kasA, ndh and 
fabG. KatG encodes catalase-peroxidase, which is a 
bifunctional enzyme, whose peroxidase has a broad 
spectrum activity that oxidize various electron donors, 
including NADP(H); AhpC encodes Alkyl hydroperoxide 
reductase C that functions in protecting cells against 
oxidative stress by peroxide detoxification, which is the 
main scavenger for endogenous hydrogen peroxides; 
InhA encodes NADH Enoyl-[acyl-carrier-protein (ACP)] 
reductase, which is essential for mycolic acid synthesis; 
kasA encodes 3-oxoacyl-[ACP]  synthase 1, which 
catalyzes fatty acid synthesis condensation reaction due 
to an addition of two carbons from malonyl-ACP to an 
acyl acceptor; Ndh encodes NADH dehydrogenase, 
which transfer electron from NADH in the respiratory 
chain to ubiquinone, where this redox reaction does not 
coincide with proton translocation. Two main molecular 
mechanisms that cause isoniazid resistance are 
mutations in the katG and inhA, which most often occurs 
in the promoter region of the katG, and inha genes. 
Activated isoniazid interferes with the synthesis of 
mycolic acid through inhibition of NADH enoyl-ACP 
reductase, which is encoded by inhA, and causes the 
MTB cell wall to become more permeable to anti-TB 
drugs [15-19]. Therefore, mutations in promoter region of 
fabG-inhA operon, which causes overexpression of inhA 
or decrease in inhA affinity to activated isoniazid, 
contribute to low-level resistance. Mutations in fabG-
inhA operon are less frequent than mutations in the katG 
[20].  
Rifampicin binds MTB RNA polymerase b-subunit, 
which is encoded by rpoB gene, and inhibits messenger 
RNA elongation. Therefore, mutations in the rpoB gene 
cause rifampicin resistance, which are found in most 
rifampicin resistant MTB clinical isolates [15-19]. The 
main mechanism in MTB pyrazinamide resistance is a 
mutation in pncA gene that encodes pyrazinamidase. 
Pyrazinamidase is an enzyme, which converts 
pyrazinamide into pyrazinoic acid that is active in 
inhibiting MTB. Therefore, mutations in pncA abolish the 
conversion ability and cause pyrazinamide resistance, 
which is revealed by a strong correlation between pncA 
mutations and MTB resistance to pyrazinamide.  The 
mutations mostly occur at an open reading frame of 561 
bp, or in an area of 82 bp that is suspected as a promoter 
[21]. 
Mutations in MTB for ethambutol resistance are less 
studied compared to those of isoniazid, rifampicin, and 
pyrazinamide. Mutations in embB i.e. in codons 406, 
354, 319 and 306 were associated with ethambutol 
resistance [22].  
Second-line drugs for the treatment of TB are 
fluoroquinolones including ofloxacin, levofloxacin, and 
moxifloxacin. The target of fluoroquinolone in MTB is 
type II DNA gyrase (topoisomerase). DNA gyrase, which 
is a tetramer, consists of subunits A and B that is 
encoded by gyrA and gyrB genes. Both genes are often 
found to be associated with fluoroquinolone resistance 
[10, 23]. 
Another second line drugs for MDR-TB are 
aminoglycosides such as kanamycin, amikacin, and 
capreomycin. Kanamycin and amikacin bind to 16S 
rRNA of small 30S ribosome subunits, thus cause protein 
synthesis inhibition. The 16S rRNA is encoded by rrs. 
The most common mutations occurred in A1401G rrs 
that were identified in 30-90% of amikacin and 
kanamycin resistant MTB strains. Capreomycin inhibits 
phenylalanine synthesis in MTB ribosome, thus causes 
translation inhibition.   Phenylalanine ribosomal 
synthesis is also encoded by rrs.  Therefore, mutations 
in the region of rrs gene cause capreomycin resistance. 
Besides that, capreomycin resistance can also occur 
when there is a mutation in the promoter of eis gene, 
which encode aminoglycoside acetyltransferase, in the 
form of low-level point mutation [10, 24]. 
MDR-TB diagnostic problems and solutions 
Until now, MDR-TB is one of the global problems in the 
world, especially in low-income countries like Asia. The 
highest number of TB cases, which was in India followed 
by Indonesia, was reported by WHO in 2017 [2]. 
Moreover, Indonesia has the highest levels MDR-TB and 
HIV in the world. This number continues to increase 
every year due to inadequate drug therapy and high 
resistance to anti-TB drugs. Though rapid molecular 
diagnostic test kits are available, it cannot be used to 
explain the variation and mechanism of resistance to 
anti-TB drugs. Most diagnostic tests only examine one or 
a certain combination of genes, which bear the most 
common mutation or hotspot genome area, thus a 
sample need several tests to get a complete drug 
resistance pattern that is needed to choose appropriate 
drug combination for the patient. Ideally, a diagnostic tool 
should provide complete information of whole MTB 
genome [7, 8, 19]. The rapid development in molecular 
biology may provide information of whole MTB gene 
sequence [7, 8].   
Information of whole MTB genome may increase 
knowledge on the mechanism of resistance to major anti-
TB drugs, as it may show the relation of a specific gene 
mutation with drug resistance.  Therefore, the molecular 
mechanism of a specific drug resistance is known, and 
can be used to improve the currently available 
techniques for rapid detection of MDR-TB [23, 25].
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NGS for whole genome sequencing to diagnose 
MDR TB infection 
Currently, next-generation sequencing (NGS) is widely 
used for drug resistance rapid diagnosis, so that 
prospective treatment and prognosis of patients with 
MDR-TB can be determined. Moreover, NGS can be 
used to sequence the whole-genome of MTB. However, 
there are some challenges in using NGS i.e. sample 
preparation is elaborated, so the methodology needs to 
be simplified and optimized for direct sputum samples; in 
some developing countries, there is lack of capacity, and 
high cost may hamper its use in global surveillance [3]. 
NGS provides options to detect the whole 
characteristics of MDR-TB. Unlike other molecular tests 
for MDR-TB, which relies on indirect MTB identification 
by a series of limited resistance mutations through 
hybridization of a probe to a specific genetic sequence, 
the NGS may provide detailed whole genome 
information. In NGS, each genome parts are sequenced 
several times, so this assessment provides accurate 
data and insight into the presence of genetic 
polymorphisms [26]. Therefore, NGS can confirm and 
assess genome level mutations that cannot be detected 
by other molecular tests. Moreover, NGS is flexible and 
can be programmed for various applications, such as for 
assessment of genetic information of co-existing micro 
organisms other than MTB that is present in a clinical 
sample [10]. 
Despite the challenges, the benefits of NGS remain 
more compared to other methods, when they are used 
for diagnosis, to determine appropriate treatment, and 
epidemiology. The benefits of NGS include time for faster 
diagnosis of MTB (from weeks in other methods to hours 
in NGS), the amount of information provided (information 
about strains, whether single or multiple infection; 
distinguishing recurrence from re-infection; drug 
resistance profile; and  chain of transmission) and 
comfort (potential to combine diagnosis, drug resistance, 
and epidemiological analysis) that can be collected in 
real-time.  In addition, NGS can be done on direct clinical 
specimens or cultured MTB isolates [27]. 
Apart from the benefits over other molecular methods, 
the use of NGS is hindered in low and middle-income 
countries, as NGS needs high cost, trained operator, 
special means for data analysis/storage, and plug-and-
play device to directly sort information from primary 
clinical samples, which are not readily available in those 
countries [10, 27]. 
Both phenotype and genotype tests have been used 
to detect MTB drug resistance to various types of drugs. 
The phenotype test is obtained by culture, which requires 
a long time from several weeks to months, while 
genotyping may shorten the time, so this method, 
especially those using NGS is highly needed [28]. 
Whole Genome Sequencing (WGS) is a method to 
determine the nucleotide sequence of certain genomes, 
which are the genetic material of whole cells or 
microbes.28 This method might obtain  genetic and 
epidemiological data, as well as indications of cross 
contamination risk, with high sensitivity [29, 30]. The 
WGS provides more precise and accurate information 
and improves understanding of MTB pathogenesis, 
immunology, and transmission [31]. 
WGS requires a genome as a reference to show 
various genetic mutations/sample variations. The 
genome, which is the most used as a reference, is MTB 
H37Rv genome with worldwide distribution and wide 
usage. The H37Rv genome is one of the best for curating 
MTB, due to transcriptomic and proteomic data sources 
that are available in the world. In molecular epidemiology 
and phylogenetic studies, mutations are associated with 
anti-tuberculosis drug resistance in MTB [23]. 
Various NGS platforms  
NGS, which is a "high throughput, massive and parallel" 
sequencing method,  can be used to assess the 
sequence of a whole genom where all genes are  
ordered along the whole target genom in a single 
biochemical reaction. This technique sort multiple DNA 
fragments in parallel, assemble and map them according 
to the reference genome using bioinformatic analysis 
[10, 32]. 
To obtain the maximum potential of NGS in a clinical 
setting to improve TB diagnosis and management, the 
NGS workflow and platform should be understood, so 
that optimal integration of NGS into existing laboratory 
workflows can be achieved [6, 33]. There are two main 
NGS platforms, i.e. that works by producing relatively 
short DNA sequences (<1000 base pairs), or longer DNA 
sequences (long reads of > 5,000 base pairs in average). 
The speed to get detailed information from NGS holds 
the potential to increase the accuracy of MDR-TB 
diagnosis, speed up TB treatment, as well as better 
understand TB epidemiology. NGS provides information 
in the form of thousands of millions of varying length 
reading to be assembled into longer sequences or even 
the whole genome, using bioinformatics. In addition, 
NGS platforms might use different sequencing chemistry 
(Table 1) [34, 35].  
All NGS platforms use similar basic workflow to get 
sequence readings from clinical samples, which consist 
of: DNA extraction, purification, target specific 
enrichment, and data analysis. DNA extraction from 
clinical samples (sputum/sediments) or cultured isolates 
should have sufficient yield, integrity, and purity. High 
quality DNA is crucial in NGS, especially WGS, thus 
efficient DNA extraction and purification methods are 
highly important. The DNA extraction method should be 
able to break the MTB cell wall to release the DNA to be 
purified. After purification, the next step is target specific 
enrichment. The resulting DNA fragments are then 
sorted in parallel, followed by data analysis, where the 
fragments are mapped according to the reference 
genome using bioinformatics special software [10]. 
Whole genome sequencing can be used as a tool to 
determine sequence variations in epidemiology and to 
determine the source of infection and transmission 
pattern between various patients. WGS uses NGS 
technology that can generate millions of brief readings 
from the entire genome, which is then analyzed by a 
special software [32].
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Specific target enrichment 
Next generation sequencing needs to do specific target 
enrichment that aims to eliminate genomic DNA regions 
that are not of interest in a certain experiment. By 
targeting specific areas, a greater sequence information 
is obtained for the areas of interest. In addition, time, 
resources and cost can be reduced, so that more 
individual samples can be analyzed. The specific target 
enrichment strategy can be carried out by various 
approaches to capture specific sequences of interest, i.e: 
hybrid capture, selective circularization, and PCR 
amplification [36]. 
Hybrid Capture is conducted using  nucleic acid 
sequences, which are derived from input samples, to be 
specifically hybridize to pre-prepared DNA fragments  
that are complementary to the target area of interest, so 
that the target area of interest can be captured, isolated, 
and enriched, either on a solid support or in solution [36]. 
Selective circularization is conducted using molecular 
inversion probes (MIP), or gap-fill padlock or selector 
probes in the form of single strand (ss) DNA circles, 
which contain the  target areas to be enriched. The ss 
DNA circles, which are formed by gap filling and ligation 
in such a way, are used for selective amplification of the 
target area of interest [36]. 
PCR Amplification is conducted using polymerase 
chain reaction (PCR) method, which is directed to the 
target areas of interest, by carrying out many remote 
PCRs in parallel, in limited quantities. The PCR method 
is very multiplex that amplifies a very large number of 
short fragments [36]. 
Next generation sequencing methods 
There are several NGS methods that need to be known 
and are often used for diagnostic tools. They are WGS, 


























WGS is a method to analyse the entire sequence of a 
cell whole genome at a single time to provide the most 
comprehensive information of the genome.  Therefore, 
WGS provides the most comprehensive data on a certain 
organism, due to its ability to show the profile of an entire 
genome; thus WGS enables scientists to find genes or 
variants that were previously unknown, and can provide 
large amounts of data in a short time. WGS can even 
predict the likelihood of genetic disorders,  which can be 
mediated through lifestyle or environmental changes,  to 
help in prevention of the occurrence of the disorders [37]. 
The second method is the targeted NGS. The targeted 
NGS is a type of NGS that focuses on specific genome 
areas, and scrutinize genome specific areas for deeper 
analysis. Therefore, it is faster and more cost-effective 
than WGS, but produce less data compared to WGS, as 
it analyse only selected specific areas [38]. 
The third method is the shotgun NGS, which is a 
technique to determine the sequence of all 
chromosomes and the whole genome by producing 
random DNA fragments with overlapping ends, followed 
by using a computer to assemble and order the 
fragments according to the overlapping ends into the 
whole genome. Shotgun NGS begins with the 
construction of a genome library. The genome library is 
produced by fragmenting the whole genome, the 
fragments are cloned into vectors, partially sorted and 
using a computer the data are collected to produce an 
entire genome sequences that consists of all fragments, 
which form known old sequences that are called contigs.  
“A contig is a set of overlapping DNA segments that 
together represent the consensus region of DNA” (cited 
from Yin and Zheng) [39].  Many contigs are often 
separated by unknown sequences. Unknown sequences 
can be determined either by hybridization protocols 
using known contig ends, or random PCR primers to 
Platform  Sequencing 
Chemistry 
Accuracy (%) x106 reads 
/run 
Run time*  Advantages  disadvantages Reference 
number 
Roche 454 Pyrosequencing  99 1 10 hours Maximum read 
length. 
Very expensive- per Mb [34] 
Illumina Sequencing by 
synthesis  
99.9 3.4 26 hours Instrument 
development with 
time 
More expensive, relative few 
readings 
[34] 
ABI SOLiD Ligation based 
sequencing   
99.94 >700 1-2 weeks Low capital cost, 
high accuracy. 
Sequencing takes a longer 












changing the chip 
vs Illumina: higher error rate, 
longer time, fewer reads, 




Direct reading of DNA 
sequence 
Up to 99 ≥500 
Can be 
determined  
by user  
1 – 48 hours Very long reads, 
portable small size 
(palm sized), 
low capital cost 
Lower  throughput than other 
machines, lowest sing 
le read accuracy  
[35] 
*= depends on the length of sequence to be read 
Table 1: Various NGS platforms 
Country Resistance  Specimen Sensitivity  Specificity   Reference number 
China Rifampicin Isolates 97% 98% [41] 











Indonesia MDR TB Sputum  NA NA [44] 
Bangladesh 
Thailand 




Myanmar MDR-TB Isolates NA  NA [46] 
MTB= Mycobacterium tuberculosis, MDR-TB= multi-drug resistant tuberculosis, NA= not available 
Table 2: Sequencing for the diagnosis and monitoring of MDR-TB patients in Asia 
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reveal the sequence of the gap region between known 
contigs. In hybridization protocol, the sequence of the 
gap between contigs is determined by filtering the 
hybridized clone library with a probe that is generated 
from the end of previously identified contigs. In random 
PCR primers’ method, the primers are annealed to the 
ends of two known contigs, and thus fill the gap and 
reveal the unknown sequence [39]. 
A special approach, which can be incorporated into the 
three methods are multiplexing, also called pooling, so 
that several samples can be processed simultaneously, 
to save costs and time. Multiplexing requires the addition 
of a barcode (index) to the sample so that they can be 
identified after being sorted. Samples used for 
hybridization catches can be duplicated after library 
preparation, but before target capture (enrichment). 
Samples used for sequential amplification must be 
transformed into libraries and enriched through individual 
PCR amplification before multiplexing to be sorted [39]. 
In a population-based multi-country study conducted 
by WHO using various NGS platforms (e.g. Illumina, Ion 
Torrent) and targeted methods, the results showed that 
NGS was very accurate in diagnosing MDR-TB from 
isolates that are cultured. 9 The study assessed various 
genes, including katG, promoter inhA and fabG to assess 
isoniazid, pncA to asses pyrazinamide, rpoB to asses 
rifampicin, gyrA and gyrB to asses ofloxacin and 
moxifloxacin, rrs to asses amikacin and capreomycin, 
and rrs and eis to asses kanamycin resistance. The 
study was conducted on 7.000 patients and found that 
there was good prediction accuracy of genetic 
sequences to show resistance to isoniazid, rifampicin, 
fluoroquinolones, and injections. This study strengths 
included the fact  that the tested isolates came from a 
whole population of TB cases with a high TB or MDR-TB 
burden [10, 40].   Table 2 shows various studies that 
were conducted in Asian countries and used NGS and 
previous sequencing methods, which showed sensitivity 
and specificity of above 90% [41-46]. Most studies found 
that almost all specimens contained resistance to a 
minimum of two anti-TB drugs (isoniazid and rifampicin). 
Many studies have been carried out using NGS 
method to test drug susceptibility of MTB, in which MTB 
susceptibility testing using NGS for clinical application 
gave faster results compared to the phenotypic testing. 
Ko et al [47] studied eighteen susceptible strains with 
benign polymorphisms, to assess phenotypic and 
genotypic resistance patterns for isoniazid, rifampicin, 
ethambutol, and pyrazinamide. Thirty-nine variants were 
found in this study, and six mutations were regarded as 
causing resistance i.e.: katG c.C944G, rpoB c.C1349T, 
embB c.A916G and c.G918A, gyrA c.C269T and rpsL 
c.A128G. There were two main causes of isoniazid 
resistance, which were in katG and inha, but a most 
common variant, which was katG R463L, was regarded 
as a benign polymorphism. On the other hand, the most 
common resistant mutation, which was in S315T katG 
promoter area, was mostly found in Indonesia.The 
rifampicin rpoB mutation occurred in codon 407-533, and 
gave rise to S450L variant. For ethambutol resistance, 
mutation occurred in codon 306 of embB, while 
pyrazinamide resistance was due to two pncA mutations 
that might cause frame-shift mutations. 
A recent study compared phenotypic testing with NGS 
Illumina platform to assess various TB drug resistance 
on overall isolates, and provided interpretations of 
mutations in katG, inha, fabG promoters, rpoB, pncA, 
gyrA, gyrB, rrs, and eis genes. The NGS was carried out 
by standard approaches to assess MTB mutations and 
provide drug resistance genetic sequencing data.  The 
data was obtained by sorting all relevant genomes/genes 
to the target genome region of katG, inha, and fabG 
promoters for isoniazid, rpoB for rifampicin, pncA for 
pyrazinamide, and gyrA/gyrB for fluoroquinolones. The 
results on isolates from 7094 TB patients showed that 
overall sensitivity value of NGS to predict genetic 
resistance varies between various drugs. Good accuracy 
of sensitivity values was found for first-line drugs (katG 
promoter, inha, fabG, and rpoB) compared to second-
line drug resistance, but lowest for detection of 
pyrazinamide resistance due to pncA mutation [10, 13].  
Several studies showed that the main cause (96%) of 
rifampicin resistance was due to mutations, which 
occurred in the centre  of a 81-base pair  region in rpoB 
gene, and rpoB S531L was the most common mutation 
in clinical MTB isolates. In countries around the world, 
40%-93% of all rifampicin resistant MTB isolates was 
due to rpoB S450L mutations. In addition, the most 
extensive rifampicin resistance was due to rpoB gene 
single amino acid mutation in codon 445 that changed 
His [CAC] to Tyr [TAC] [15-19]. 
Falzon et al [23]  did a meta-analysis of individual 
MDR-TB patient data and concluded that the most 
common fluoroquinolone resistance was due to 
GCG90GTG and GAC94GGC mutations; where isolates 
with a GAC94GGC mutation usually showed a Minimum 
Concentration (MIC) that is higher compared to a 
GCG90GTG mutation. 
A study concluded that NGS provided information that 
enable easier differentiation between various strains, 
and assessment of MTB genetic heterogeneity, by which 
MDR-MTB Beijing strain complex evolutionary pattern 
was revealed. Moreover, NGS showed more accuracy 
than other genotype methods, namely Mycobacterial 
interspersed repetitive unit- variable number tandem 
repeat (MIRU-VNTR) and Xpert MTB/RIF assay. So that 
the complex evolutionary patterns of Beijing MDR MTB 
strains in patients have been revealed using NGS [33]. 
Maningi et al study [21] using NGS showed that pncA 
gene mutation in Pyrazinamide resistance revealed 
additional diagnostic values that were accurate and 
might be considered in routine testing for MDR-TB 
management strategies. Eighty-eight isolates were 
sequenced using NGS Ion Torrent (PGM) platform, and 
55 wild type and 33 pncA gene mutation containing 
isolates were found. PncA mutations in 33 of these 
isolates represent nucleotide substitution (missense 
mutations), deletions that cause amino acid substitution 
or frame shift mutation, and insertion. Using the NGS, 
additional mutations in 6 isolates were detected that 
were undetected in previous Sanger sequencing. 
A study by Daum et al [17] in Ukraine used NGS to 
analyze MDR mutations in inhA, katG, and rpoB 
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genomes and showed that all clinical isolates (100%) 
showed inhA wild type gene, among which 23% had 
mutation in inhA promoter region, while the most 
frequent mutation (89%) that caused isoniazid resistance 
occurred in katG S-315-T. For rifampicin resistance, 95% 
mutations occurred in rpoB ‘81-bp nucleus region’, which 
was rifampicin resistance determining region (RRDR), 
and most mutations occurred in positions 516 (D-516-V), 
526 (H-526-Y or D) and 531 (S -531-L). Further, two 
rifampicin resistant isolates were isoniazid sensitive, and 
five rifampicin resistant strains showed heteroresistance, 
i.e.: two strains of S-531-S/F /L, which are rare mutations  
with one wild type and two mutant residues, two strains 
of S-531-S / L and one strain of H-526-H / D, where the 
three later strains were double mutants.  
For amikacin and kanamycin resistance, rrs A1401G 
mutation, which caused high level resistance to both 
drugs, was the most common in Thailand (21 of 29 
strains). This mutation showed cross-resistance with 
capreomycin. In addition, mutations in eis promoter 
caused low-level resistance to amikacin, which was 
found in five out of 29 strains that were kanamycin 
resistant [24]. Miotto et al [18] concluded that the 
mutations, which were associated with amikacin 
resistance, were only rrs A1401G and G1484T, and rrs 
mutations were associated with high MIC in a variety of 
different media.  
Conclusion  
Multi drug resistant is one of the global problems that 
occurs in almost all regions of the world, especially in 
Asian populations. In recent years, the NGS can be used 
as a rapid diagnostic tool in describing a patient's MDR-
TB status. Almost all gene mutation, which causes 
resistance, can be found by this method. It is hoped that 
by using NGS, patient diagnosis and management will 
be more optimal, so that mortality due to MDR TB can be 
reduced. 
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